Publications by authors named "YaoYu Ning"

Claim this Profile
D
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Wei-Sheng Huang, Feng Li, Yongjin Gong, Yun Zhang, Willmen Youngsaye, Yaoyu Ning

Bioorg Med Chem Lett· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobocertinib (TAK-788): A Targeted Inhibitor of Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
Francois Gonzalvez, Sylvie Vincent, Theresa E Baker, Alexandra E Gould, Shuai Li, Yaoyu Ning

Cancer Discov· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Yaoyu Ning

Clin Cancer Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Wei-Sheng Huang, Shuangying Liu, Dong Zou, Mathew Thomas, Yihan Wang, Yaoyu Ning

J Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Yaoyu Ning

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning

Chem Biol Drug Des· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Victor M Rivera, Rachel M Squillace, David Miller, Lori Berk, Scott D Wardwell, Yaoyu Ning

Mol Cancer Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Mathew Thomas, Wei-Sheng Huang, David Wen, Xiaotian Zhu, Yihan Wang, Yaoyu Ning

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Wei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, Yihan Wang, Dong Zou, Yaoyu Ning

J Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Thomas O'Hare, William C Shakespeare, Xiaotian Zhu, Christopher A Eide, Victor M Rivera, Yaoyu Ning, Michael W N Deininger

Cancer Cell· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Wei-Sheng Huang, Xiaotian Zhu, Yihan Wang, Mohammad Azam, David Wen, Yaoyu Ning

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Yihan Wang, William C Shakespeare, Wei-Sheng Huang, Raji Sundaramoorthi, Scott Lentini, Yaoyu Ning

Bioorg Med Chem Lett· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alveolar macrophage cytokine response to air pollution particles: oxidant mechanisms.
Amy Imrich, YaoYu Ning, Joy Lawrence, Brent Coull, Elena Gitin

Toxicol Appl Pharmacol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The macrophage scavenger receptor SR-AI/II and lung defense against pneumococci and particles.
Mohamed S Arredouani, Zhiping Yang, Amy Imrich, Yaoyu Ning, Guozhong Qin

Am J Respir Cell Mol Biol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles.
Mohamed Arredouani, Zhiping Yang, YaoYu Ning, Guozhong Qin, Raija Soininen

J Exp Med· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Particle-epithelial interaction: effect of priming and bystander neutrophils on interleukin-8 release.
Yaoyu Ning, Florence Tao, Guozhong Qin, Amy Imrich, Carroll-Ann Goldsmith

Am J Respir Cell Mol Biol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined air pollution particle and ozone exposure increases airway responsiveness in mice.
Carroll-Ann W Goldsmith, YaoYu Ning, Guozhong Qin, Amy Imrich, Joy Lawrence

Inhal Toxicol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis